INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (Nasdaq: SPPI). Investors who purchased or otherwise acquired shares between February 28, 2013 and September 16, 2016 inclusive (the "Class Period"), are encouraged to contact the Firm in advance of the November 21, 2016 lead plaintiff motion deadline.

If you purchased shares of Spectrum during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that Spectrum made false and/or misleading statements and/or failed to disclose that: the FDA previously questioned whether the data from the 611 and 612 Studies (the names of the Phase 3 studies for apaziquone) were clinically significant; that the FDA instructed the Company in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and that as a result of the above, the Company's public statements regarding its business, operations and prospects were materially false and misleading at all relevant times. When this information was disclosed, shares of Spectrum declined in value.

If you wish to learn more about this lawsuit at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

If you liked this article you might like

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Merger Buzz Drives Akorn to Top of Health Chart in April

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Biotech Premarket Movers: Spectrum, BioCryst, Curis

Spectrum Pharma, FDA and the Buried Truth About a Bladder Cancer Drug Meeting